Efficacy of revefenacin based on GOLD 2017 categories: reanalysis of phase 3 data in patients with COPD Source: International Congress 2019 – COPD clinical trials: inhaled and oral therapies Year: 2019
Stage 0 in GOLD does not predict future clinical COPD Source: Eur Respir J 2002; 20: Suppl. 38, 401s Year: 2002
Late Breaking Abstract - Adherence to GOLD recommendations in Italian COPD patients stratified by GOLD groups A–D: The MISTRAL study Source: International Congress 2017 – Primary care pulmonary rehabilitation, multimorbidity and organisation of care Year: 2017
Discovery of novel disease-related biomarkers for GOLD stage II COPD: A prospective exploratory clinical study Source: Annual Congress 2010 - Novel mechanisms in COPD Year: 2010
Combined assessment according to the new GOLD guidelines and its relation to outcome in COPD Source: Annual Congress 2012 - GOLD guidelines 2011: new assessment of COPD Year: 2012
Prediction of the clinical course of COPD using the old and the new GOLD classification Source: Annual Congress 2012 - GOLD guidelines 2011: new assessment of COPD Year: 2012
Rehabilitation programs in patients in different severity stage of COPD (GOLD II-to-IV): analysis of the results Source: Eur Respir J 2005; 26: Suppl. 49, 69s Year: 2005
Validation of non-spirometric predictors of COPD to the GOLD stage classification Source: Eur Respir J 2002; 20: Suppl. 38, 123s Year: 2002
Implementation of the GOLD 2017 disease classification in a real-life COPD cohort Source: International Congress 2018 – How far are we in terms of predicting mortality and exacerbations in COPD? Year: 2018
Methodology of clinical trials in COPD exacerbations: Eligibility criteria and endpoint selection. Source: International Congress 2018 – Innovative therapies in asthma and COPD Year: 2018
The same COPD patients, different GOLD criteria – what are the consequences of changing GOLD 2007-2011-2017 recommendations? Source: International Congress 2018 – Epidemiology of COPD : from exarcebations and comorbidities to asthma-COPD overlap syndrome (ACOS) Year: 2018
Health status in the GOLD guidelines era. Assessing the new COPD severity staging criteria Source: Eur Respir J 2002; 20: Suppl. 38, 251s Year: 2002
The impact of grouping patients by the 2017 GOLD COPD strategy on response to therapy: post hoc results from the TONADO tiotropium+olodaterol trials Source: International Congress 2017 – What is new in COPD diagnosis and classification? Year: 2017
GOLD assessment of COPD patients: Impact of symptoms assessment choice Source: Annual Congress 2012 - GOLD guidelines 2011: new assessment of COPD Year: 2012
Effectiveness of tiotropium in low-risk patients according to new GOLD severity grading Source: Annual Congress 2012 - Translational respiratory medicine in asthma and COPD Year: 2012
Impact of grouping patients by 2017 GOLD strategy assessment criteria: a post hoc analysis of the TONADO and OTEMTO trials Source: International Congress 2017 – COPD management: new findings from large studies Year: 2017
Quantification and treatment patterns of real-world patients classified by the GOLD 2011 strategy Source: Annual Congress 2012 - Trials in COPD: novel treatments and insights Year: 2012
Combined COPD assessment using the new GOLD guidelines Source: Annual Congress 2012 - GOLD guidelines 2011: new assessment of COPD Year: 2012
The current ERS, BTS, ATS and GOLD classification criteria underestimate the impact of COPD on patients Source: Eur Respir J 2002; 20: Suppl. 38, 254s Year: 2002
An Italian, observational, multicenter trial to describe the therapeutic approach according to COPD GOLD guidelines during three years of observation: The MISTRAL study Source: International Congress 2014 – Clinical assessment of airway diseases Year: 2014